• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Cryo-Cell International Inc. (Amendment)

    2/14/22 12:44:18 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care
    Get the next $CCEL alert in real time by email
    SC 13G/A 1 cryo13ga4-020421.htm
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C.  20549
    SCHEDULE 13G
    (RULE 13D - 102)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b)
    (Amendment No. 4)*
    Cryo-Cell International, Inc.
    (Name of Issuer)
    Common Stock, par value $0.01
    (Title of Class of Securities)
    228895108
    (CUSIP Number)
    December 31, 2021
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    (Page 1 of 10)


    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    IsZo Capital LP
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [x]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    482,931
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    482,931
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    482,931
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    5.7%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    PN



    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    IsZo Capital GP LLC
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [x]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    482,931
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    482,931
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    482,931
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    5.7%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    OO



    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    IsZo Capital Management LP
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [x]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    482,931
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    482,931
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    482,931
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    5.7%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    PN


    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Brian L. Sheehy
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [x]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    United States
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    482,931
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    482,931
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    482,931
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    5.7%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    IN, HC



    This Schedule 13G reflects the beneficial ownership of the Reporting Persons (as defined below) as of December 31, 2021.
    Item 1(a).
    Name of Issuer:
    Cryo-Cell International, Inc. (“Issuer”)
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
    700 Brooker Creek Blvd.
    Oldsmar, Florida 34677
    Item 2(a).
    Name of Persons Filing:
    The names of the persons filing this statement on Schedule 13G are (collectively, the “Reporting Persons”):
    -            IsZo Capital LP (the “Fund”).

    -            IsZo Capital GP LLC (“IsZo GP”).

    -            IsZo Capital Management LP (“ICM”).

    -            Brian L. Sheehy (“Mr. Sheehy”).

    IsZo GP is the general partner of the Fund.  ICM is the investment manager of the Fund.  Mr. Sheehy is the managing member of IsZo GP and the President of the general partner of ICM.  IsZo GP, ICM and Mr. Sheehy may each be deemed to have voting and dispositive power with respect to the shares of Common Stock (as defined below) held by the Fund.
    Item 2(b).
    Address of Principal Business Office or, if None, Residence:
    Each of the Reporting Persons has a business address at 590 Madison Avenue, 21st Floor, New York, New York 10022.
    Item 2(c).
    Citizenship:
    Mr. Sheehy is a citizen of the United States.
    IsZo GP is a limited liability company formed under the laws of the State of Delaware.
    Each of the Fund and ICM is a limited partnership formed under the laws of the State of Delaware.
    Item 2(d).
    Title of Class of Securities:
    Common Stock, $0.01 par value per share (the “Common Stock”)
    Item 2(e).
    CUSIP Number:
    228895108

    Item 3.
    If This Statement is Filed Pursuant to Rule 13d 1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Exchange Act.
           
     
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Exchange Act.
           
     
    (c)
    [ ]
    Insurance company defined in Section 3(a)(19) of the Exchange Act.
           
     
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act.
           
     
    (e)
    [x]
    Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
     
    (f)
    [ ]
    Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
     
    (g)
    [ ]
    Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
     
    (h)
    [ ]
    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
     
    (i)
    [ ]
    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
     
    (j)
    [ ]
    Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
           
     
    (k)
    [ ]
    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

    If this statement is filed pursuant to Rule 13d-1(c), check this box [  ]
    Item 4.
    Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a)
    Amount beneficially owned:
    As of the close of business on December 31, 2021, the Reporting Persons may be deemed to have beneficially owned 482,931 shares of Common Stock.

    (b)
    Percent of class:
    The aggregate percentage of Common Stock reported owned by each person named herein is based upon 8,529,647 shares outstanding, which is the total number of common shares outstanding on October 12, 2021 as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on October 15, 2021. As of the close of business on December 31, 2021, the Reporting Persons may be deemed to have beneficially owned approximately 5.7% of Common Stock outstanding.

    (c)
    Number of shares as to which such person has:

    (i)
    Sole power to vote or to direct the vote
    See Cover Pages Items 5-9.


    (ii)
    Shared power to vote or to direct the vote
    See Cover Pages Items 5-9.

    (iii)
    Sole power to dispose or to direct the disposition of
    See Cover Pages Items 5-9.

    (iv)
    Shared power to dispose or to direct the disposition of
    See Cover Pages Items 5-9.
    Item 5.
    Ownership of Five Percent or Less of a Class.
    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group.
    See Exhibit B to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on February 14, 2018.
    Item 9.
    Notice of Dissolution of Group.
    Not applicable.
    Item 10.
    Certification.
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURES
    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.
    Dated:  February 14, 2022
     
    ISZO CAPITAL LP
     
    By IsZo Capital GP LLC, its General Partner
       
       
    By:
    /s/ Brian L. Sheehy 
         
    Brian L. Sheehy, Managing Member

     
    ISZO CAPITAL GP LLC
       
     
    By:
    /s/ Brian L. Sheehy 
       
    Brian L. Sheehy, Managing Member

     
    ISZO CAPITAL MANAGEMENT LP
     
    By: IsZo Management Corp., as General Partner
       
       
    By:
    /s/ Brian L. Sheehy 
         
    Brian L. Sheehy, Managing Member

     
    /s/ Brian L. Sheehy 
     
    Brian L. Sheehy



    Get the next $CCEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CCEL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CCEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cord Blood Banking Leader Cryo-Cell Announces Cash Dividend

      Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that, as a result of the current economic environment and other capital allocation alternatives, its Board of Directors has approved the payment of a reduced, quarterly cash dividend of $0.15 per share of common stock to be paid to its shareholders of record as of the close of business on May 21, 2025. The dividend is expected to be paid on May 30, 2025. The Board of Directors will continue to evaluate the Company's dividend policy on a regular basis and may change such policy at any time. There is no assurance that

      5/8/25 5:00:00 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2025 Financial Results

      Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2025. Financial Results Revenue The revenues for the first quarter of fiscal 2025 were $7.97 million compared to $7.85 million for the first quarter of fiscal 2024. The revenues for the first quarter of fiscal 2025 consisted of $7.87 million in processing and storage fee revenue, $21,000 in product revenue and approximately $82,000 in public banking revenue compared to $7.81 million in processing and storage fees, approximately $3,000 in product revenue and approximat

      4/15/25 8:30:00 AM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • Cord Blood Banking Leader Cryo-Cell Announces Regular Quarterly Cash Dividend and Pause of Strategic Initiatives

      Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a quarterly cash dividend of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on February 14, 2025. The dividend is expected to be paid on February 28, 2025. The Board of Directors will continue to evaluate the Company's dividend policy on a regular basis and may change such policy at any time. There is no assurance that future dividends will be paid. The Company also announced that it has paused its strateg

      1/29/25 4:15:00 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care

    $CCEL
    SEC Filings

    See more
    • Cryo-Cell International Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

      8-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)

      5/22/25 5:00:13 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • Cryo-Cell International Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)

      5/8/25 5:00:08 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-Q filed by Cryo-Cell International Inc.

      10-Q - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)

      4/14/25 5:00:24 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care

    $CCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Information Officer Mikulinsky Oleg

      4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)

      1/23/25 5:00:12 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 4 filed by Chairman, Co-CEO Portnoy David

      4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)

      1/23/25 5:00:05 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 4 filed by VP Finance, CFO Taymans Jill M

      4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)

      1/23/25 5:00:03 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care

    $CCEL
    Leadership Updates

    Live Leadership Updates

    See more
    • Cryo-Cell International Announces Changes To Its Board of Directors

      MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NASDAQ:CCEL), the leader in cord blood and cord tissue cryopreservation services, announces the appointment of Mr. Mark Portnoy and Mr. Daniel Mizrahi to the Company's Board of Directors, replacing Mr. George Gaines and Jonathan Wheeler, M.D., who have resigned in their capacity as Directors. Mr. Gaines has chosen to retire while Dr. Wheeler has resigned for health reasons. The Board of Directors voted unanimously in favor of adding Mr. Mark Portnoy and Mr. Daniel Mizrahi as members of the Board. Mr. Portnoy is a Co-CEO of the Company and previously served as a member of the Board of Directors from 2011-2020. Mr. Miz

      9/20/21 6:05:23 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care

    $CCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cryo-Cell International Inc. (Amendment)

      SC 13G/A - CRYO CELL INTERNATIONAL INC (0000862692) (Subject)

      2/14/23 4:14:29 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Cryo-Cell International Inc. (Amendment)

      SC 13G/A - CRYO CELL INTERNATIONAL INC (0000862692) (Subject)

      2/14/22 12:44:18 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care

    $CCEL
    Financials

    Live finance-specific insights

    See more
    • Cord Blood Banking Leader Cryo-Cell Announces Cash Dividend

      Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that, as a result of the current economic environment and other capital allocation alternatives, its Board of Directors has approved the payment of a reduced, quarterly cash dividend of $0.15 per share of common stock to be paid to its shareholders of record as of the close of business on May 21, 2025. The dividend is expected to be paid on May 30, 2025. The Board of Directors will continue to evaluate the Company's dividend policy on a regular basis and may change such policy at any time. There is no assurance that

      5/8/25 5:00:00 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • Cord Blood Banking Leader Cryo-Cell Announces Regular Quarterly Cash Dividend and Pause of Strategic Initiatives

      Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a quarterly cash dividend of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on February 14, 2025. The dividend is expected to be paid on February 28, 2025. The Board of Directors will continue to evaluate the Company's dividend policy on a regular basis and may change such policy at any time. There is no assurance that future dividends will be paid. The Company also announced that it has paused its strateg

      1/29/25 4:15:00 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • Cord Blood Banking Leader Cryo-Cell Declares Initiation of Regular Quarterly Cash Dividend

      Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a regular quarterly cash dividend at an initial rate of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on November 15, 2024. The dividend is expected to be paid on November 29, 2024. The Board of Directors plans to evaluate the dividend policy on a regular basis, considering the Company's earnings, cash flows, and alternative uses of and access to capital that may arise. Depending on these factors, future di

      10/30/24 8:45:00 AM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care